Egetis Therapeutics has completed a directed new issue of 35,9 million ordinary shares at SEK 5,10 per share, raising approximately SEK 183 million before transaction costs. The issue was oversubscribed and included American biotech investors such as Frazier Life Sciences, Inv, petrichor and Woodline Partners, as well as Swedish investors who Fourth AP Fund and LinzThe capital will finance the development of tiratricol and the submission of the NDA application in the United States.
|
Published October 3, 2025
Egetis carries out a directed share issue of SEK 183 million
Notes
Klarias partner CNX startar produktion av migränfilm
Sofinnova Partners raises EUR 650 million in new fund
Merck acquires Cidara for approximately USD 9,2 billion
Coegin Pharma launches first Follicopeptide product
Ascelia Pharma receives FDA acceptance for Orviglance application
Diamyd Medical passes safety review ahead of Phase III readout
Egetis reports positive results from the ReTRIACt study
NEWSLETTER
Today's news roundup
News roundup Monday, November 17
Upcoming events
MedTech Summit 2026
A new, much-needed MedTech forum in one of Europe's leading life science clusters. As the first event of its kind...
Recommended
Pila Pharma stands out in next-generation obesity pipeline
Novo Nordisk challenges Pfizer in billion-dollar battle for Metsera
New major investment will strengthen Europe's life science sector
The pharmaceutical sector is riding a USD 61,6 billion R&D wave
SwedenBIO wants to give growth power to the industry
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account